Literature DB >> 8605881

Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation.

C Van Lint1, S Emiliani, M Ott, E Verdin.   

Abstract

After integration in the host cell genome, the HIV-1 provirus is packaged into chromatin. A specific chromatin disruption occurs in the HIV-1 promoter during transcriptional activation in response to TNF-alpha, suggesting that chromatin plays a repressive role in HIV-1 transcription and that chromatin modification(s) might result in transcriptional activation. We have treated several cell lines latently infected with HIV-1 with two new specific inhibitors of histone deacetylase, trapoxin (TPX) and trichostatin A (TSA), to cause a global hyperacetylation of cellular histones. Treatment with both drugs results in the transcriptional activation of the HIV-1 promoter and in a marked increase in virus production. Dose-response curves and kinetic analysis show a close correlation between the level of histone acetylation and HIV-1 gene expression. In contrast, both TPX and TSA have little or no effect on HIV-1 promoter activity following transient transfection of an HIV-1 promoter-reporter plasmid. Activation of HIV-1 transcription by TSA and TPX treatment occurs in the absence of NF-kappa B induction. Chromatin analysis of the HIV-1 genome shows that a single nucleosome (nuc-1) located at the transcription start and known to be disrupted following TNF-alpha treatment, is also disrupted following TPX or TSA treatment. This disruption is independent of transcription as it is resistant to alpha-amanitin. These observations further support the crucial role played by nuc-1 in the suppression of HIV-1 transcription during latency and demonstrate that transcriptional activation of HIV-1 can proceed through a chromatin modification.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605881      PMCID: PMC450009     

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  54 in total

Review 1.  The interaction of transcription factors with nucleosomal DNA.

Authors:  J J Hayes; A P Wolffe
Journal:  Bioessays       Date:  1992-09       Impact factor: 4.345

2.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.

Authors:  S Y Kao; A F Calman; P A Luciw; B M Peterlin
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

3.  Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone.

Authors:  K A Clouse; D Powell; I Washington; G Poli; K Strebel; W Farrar; P Barstad; J Kovacs; A S Fauci; T M Folks
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

4.  Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.

Authors:  C H Herrmann; A P Rice
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

5.  Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line.

Authors:  T M Folks; J Justement; A Kinter; C A Dinarello; A S Fauci
Journal:  Science       Date:  1987-11-06       Impact factor: 47.728

6.  Structural arrangements of transcription control domains within the 5'-untranslated leader regions of the HIV-1 and HIV-2 promoters.

Authors:  K A Jones; P A Luciw; N Duchange
Journal:  Genes Dev       Date:  1988-09       Impact factor: 11.361

7.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B.

Authors:  L Osborn; S Kunkel; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

8.  Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus.

Authors:  J A Garcia; F K Wu; R Mitsuyasu; R B Gaynor
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

9.  Purification of the human immunodeficiency virus type 1 enhancer and TAR binding proteins EBP-1 and UBP-1.

Authors:  F K Wu; J A Garcia; D Harrich; R B Gaynor
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

10.  A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B.

Authors:  E B Traenckner; S Wilk; P A Baeuerle
Journal:  EMBO J       Date:  1994-11-15       Impact factor: 11.598

View more
  281 in total

1.  Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity.

Authors:  C Van Lint; C A Amella; S Emiliani; M John; T Jie; E Verdin
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter.

Authors:  Marina Lusic; Alessandro Marcello; Anna Cereseto; Mauro Giacca
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

3.  Repression of the HIV-1 5' LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors.

Authors:  Lindsey Reynolds; Christopher Ullman; Michael Moore; Mark Isalan; Michelle J West; Paul Clapham; Aaron Klug; Yen Choo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

Review 4.  HIV latency.

Authors:  Robert F Siliciano; Warner C Greene
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

5.  Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Authors:  Frank Wolschendorf; Alberto Bosque; Takao Shishido; Alexandra Duverger; Jennifer Jones; Vicente Planelles; Olaf Kutsch
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

6.  Combinatorial latency reactivation for HIV-1 subtypes and variants.

Authors:  John C Burnett; Kwang-Il Lim; Arash Calafi; John J Rossi; David V Schaffer; Adam P Arkin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

Review 7.  Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells.

Authors:  Alberto Bosque; Vicente Planelles
Journal:  Methods       Date:  2010-10-21       Impact factor: 3.608

8.  Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells.

Authors:  Hao Yin; Yuhao Zhang; Xin Zhou; Huanzhang Zhu
Journal:  Mol Biol Rep       Date:  2010-12-23       Impact factor: 2.316

9.  Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency.

Authors:  Olaf Kutsch; Etty N Benveniste; George M Shaw; David N Levy
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.

Authors:  Nancie M Archin; Amy Espeseth; Daniel Parker; Manzoor Cheema; Daria Hazuda; David M Margolis
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.